biosimilars

Novartis tips Lucentis to weather the arrival of biosimilar copies in Europe
Biopharma Reporter
Thu, 08/11/22 - 12:30 pm
Novartis
Lucentis
biosimilars
patents
Europe
Coherus wins FDA approval for second Lucentis biosimilar, its third drug
BioPharma Dive
Wed, 08/3/22 - 09:26 pm
Coherus Biosciences
biosimilars
Lucentis
Roche
Cimerli
Biogen, watch out: Novartis' Tysabri biosim application could portend multiple sclerosis showdown in Europe and US
Fierce Pharma
Wed, 07/27/22 - 10:58 am
Novartis
Biogen
multiple sclerosis
MS
Tysabri
biosimilars
Novartis asks FDA to approve biosimilar for Biogen’s top-selling MS drug
BioPharma Dive
Mon, 07/25/22 - 09:54 pm
Novartis
FDA
Biogen
biosimilars
Tysabri
MS
multiple sclerosis
FDA reviewing higher dose Hyrimoz biosimilar
Biopharma Reporter
Fri, 07/22/22 - 11:14 am
FDA
Sandoz
biosimilars
Hyrimoz
Humira
AbbVie
Biosimilar inspections still lagging as the FDA looks to clear its backlog
Endpoints
Fri, 07/22/22 - 10:11 am
biosimilars
FDA
regulatory
regulatory inspections
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
BioSpace
Thu, 07/7/22 - 10:41 am
Alvotech
AVT06
biosimilars
clinical trials
Eylea
As biosimilars gain steam, Amgen exec lays out its Humira copycat plans
Fierce Pharma
Wed, 06/22/22 - 06:57 pm
Amgen
Humira
biosimilars
More drug, fewer jabs: Novartis' Sandoz eyes EMA nod for high-concentration Humira copy
Fierce Pharma
Mon, 06/20/22 - 10:37 am
Novartis
Sandoz
AbbVie
Humira
Europe
biosimilars
autoimmune disease
EMA
Hyrimoz
Novartis’ Sandoz Launches Biosimilars Awareness Campaign to Improve Biosimilars Adoption Worldwide
Xtalks
Wed, 06/8/22 - 11:04 pm
Novartis
Sandoz
biosimilars
generics
Biogen, Samsung Bioepis launch ranibizumab-nuna in US
Ophthalmology Today
Fri, 06/3/22 - 09:11 am
Biogen
Samsung Bioepis
ranibizumab
ranibizumab-nuna
biosimilars
Roche
Lucentis
retinal disease
Novartis' Sandoz founds new initiative to expand biosimilar use more globally
Endpoints
Tue, 05/31/22 - 11:51 pm
Novartis
Sandoz
biosimilars
Microcap's effort to take on Eylea with Avastin biosimilar faces significant FDA roadblock
Endpoints
Tue, 05/31/22 - 10:51 am
Outlook Therapeutics
Avastin
biosimilars
wet age-related macular degeneration
Roche
bevacizumab
Amneal scores third biosimilar approval in three months
Biopharma Reporter
Tue, 05/31/22 - 10:31 am
Amneal
FDA
biosimilars
pegfilgrastim
Fylnetra
Amgen
Neulasta
The patent winter is coming
EP Vantage
Wed, 05/25/22 - 10:41 am
patents
biosimilars
patent cliff
Keytruda
Opdivo
Eliquis
Darzalex
Revlimid
Humira
Stelara
AbbVie
Merck
Bristol Myers Squibb
JNJ
J&J's crown jewel Stelara faces another potential rival as biosim player Alvotech touts trial win
Fierce Pharma
Tue, 05/24/22 - 04:31 pm
Alvotech
Teva Pharmaceutical
JNJ
Stelara
AVT04
biosimilars
psoriasis
Could This Biosimilar Drug Candidate Create a Blockbuster for Amgen?
Motley Fool
Mon, 05/23/22 - 06:44 pm
Amgen
biosimilars
Stelara
JNJ
Roche Wakes Up to New Competition as FDA Approves Amneal’s Avastin Biosimilar
BioSpace
Thu, 04/14/22 - 10:57 am
Amneal
FDA
bevacizumab-maly
Genentech
Roche
Avastin
biosimilars
The mysterious case of Viatris and the missing insulin label deepens
Fierce Pharma
Wed, 04/13/22 - 10:42 am
Viatris
insulin
diabetes
biosimilars
Sanofi
Lantus
product recalls
More biosimilar use could've saved Medicare and beneficiaries $84M in 2019, HHS OIG says
Endpoints
Sat, 04/2/22 - 11:46 am
biosimilars
Medicare
CMS
Medicare Part D

Pages